ROCO
4747
Market cap66mUSD
Oct 08, Last price
23.35TWD
1D
0.86%
1Q
-53.30%
Jan 2017
-28.94%
IPO
37.68%
Name
Johnson Chemical Pharmaceutical Works Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Johnson Chemical Pharmaceutical Works Co., Ltd., established in 1959 and headquartered in New Taipei City, Taiwan, is a Taiwanese company that engages in the manufacturing, importing, and distribution of pharmaceutical raw materials, active ingredients, and finished drug products. The company's diverse product portfolio addresses a wide spectrum of health conditions, encompassing areas such as the central nervous system, respiratory, cardiovascular, gastrointestinal, and endocrine systems, alongside offerings for vitamin supplementation, anti-inflammatory needs, cough and cold remedies, and pain relief. These medicinal products are available in various forms, including traditional solid oral dosages like capsules, tablets, powders, and granules, as well as specialized delivery systems such as nasal sprays.
Key people
Boxiong Huang
Chairman of the Board · since 2025
Yicong Qiu
Deputy General Manager-Business · since 2012
Yixiu Chen
Head of Finance and Accounting, Corporate Governance Officer · since 2023
Boxun Huang
Director · since 2007
Yahui Lan
Director · since 2025
Haoxi Su
General Manager, Director · since 2025
Xiaohui Su
Director · since 2025
Changrui Yang
Director · since 2025
Rongfu Yang
Director · since 2004
Dairong Zhong
Director · since 2025
Zongcheng Lai
Independent Director · since 2012
Jianfa Lan
Independent Director · since 2012
Zhiheng Li
Independent Director · since 2012
Weitai Li
Independent Director · since 2025
Shengchao Peng
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||